Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive is a forward-looking company that adopts technology enthusiastically, utilizing decades of expertise and experience [4] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Company Leadership Change - Zynex, Inc. announced the appointment of Steven Dyson as Chief Executive Officer, effective August 18, 2025 [1] - Thomas Sandgaard, the founder and Chairman of the Board since 1996, will continue to be actively involved in the company [2] Executive Experience - Steven Dyson brings over 25 years of experience in the medical technology sector, with a strong background in private equity and leadership roles in various healthcare companies [3] - His previous experience includes significant roles in companies such as KCI, Rodenstock, Healthium Medtech, Unilabs, and Neuraxpharm [3] Strategic Focus - The company aims to refocus its business strategy towards a more optimized payer mix and to return to a strong growth trajectory under Dyson's leadership [5] - Dyson expressed enthusiasm about leading Zynex and emphasized the strong foundation built by Sandgaard [5] Company Overview - Zynex develops, manufactures, markets, and sells medical devices for pain management and rehabilitation, as well as non-invasive monitoring systems for hospitals [10]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Company Overview - Zynex, Inc. is an innovative medical technology company focused on noninvasive medical devices for pain management, rehabilitation, and patient monitoring [1][10] - The company has been awarded UK patent 2617515 for a multiparameter, noninvasive sepsis monitor [1] Industry Context - Sepsis is a critical global health issue, with over 1.7 million cases annually in the United States and a mortality rate that is among the highest for medical conditions [2][3] - Globally, sepsis results in approximately 11 million deaths each year, accounting for about 20% of total deaths, with a significant portion of cases occurring in children under 5 years old [2][3] Product Development - Zynex aims to develop a noninvasive, highly accurate sepsis monitor that continuously tracks multiple physiological signals to provide real-time alerts to clinicians [3][4] - The device is expected to enhance early detection and treatment of sepsis, potentially reducing mortality rates associated with this condition [4]

Company Overview - Zynex is a medical technology company focused on non-invasive medical devices for pain management, rehabilitation, and patient monitoring [4] - The company's 2024 revenue reached $192.4 million [4, 5] - Zynex achieved a gross margin of 80% in 2024 [4, 5] - The company's net income for 2024 was $3.0 million [4] - As of March 31, 2025, Zynex held $23.9 million in cash and cash equivalents [4] Market and Growth - The company operates in an addressable market exceeding $4.6 billion [5, 10] - The electrotherapy market is estimated at $950 million [10, 12] - The patient monitoring market is estimated at $3.6 billion [10, 21] Financial Highlights - The company's 5-year revenue CAGR is 33% [5, 51] - The company's EBITDA for 2024 was $10.9 million [5] - The company's adjusted EBITDA for 2024 was $10.851 million, representing 6% of net revenue [58]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Zynex, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Zynex securities between March 13, 2023, and March 11, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 19, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] Group 3: Allegations Against Zynex - The lawsuit alleges that Zynex failed to disclose that it shipped products in excess of need, which inflated its revenue [4] - It is claimed that Zynex's practice of filing false claims attracted scrutiny from insurers, leading to potential adverse consequences, including removal from insurer networks and federal penalties [4] - The lawsuit asserts that the positive statements made by Zynex regarding its business and operations were materially misleading [4]

Core Viewpoint - Zynex, Inc. is facing allegations of issuing materially false and misleading statements regarding its business practices, particularly related to inflated revenue and improper product shipments during the class period from March 13, 2023, to March 11, 2025 [1]. Group 1: Allegations Against Zynex, Inc. - The complaint alleges that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [1]. - The company's practice of filing false claims has drawn scrutiny from insurers, including the U.S. military health insurance program, Tricare [1]. - As a result of these practices, Zynex is likely to face adverse consequences, including potential removal from insurer networks and penalties from the federal government [1]. - The positive statements made by the defendants regarding the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased shares of ZYXI during the specified class period are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment [1][2]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is May 19, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the lifecycle of the case [2].

Core Viewpoint - A class action securities lawsuit has been filed against Zynex, Inc. alleging securities fraud that affected investors between March 13, 2023, and March 11, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [2]. - It is alleged that the company's practice of filing false claims attracted scrutiny from insurers, including the U.S. military health insurance program, Tricare [2]. - The lawsuit suggests that Zynex is likely to face adverse consequences, such as removal from insurer networks and penalties from the federal government [2]. - Defendants' positive statements regarding the company's business, operations, and prospects are claimed to be materially misleading and lacking a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses in Zynex, Inc. during the relevant time frame have until May 19, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

NEW YORK, May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zynex, Inc. ("Zynex, Inc." or the "Company") (NASDAQ: ZYXI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zynex, Inc. investors who were adversely affected by alleged securities fraud between March 13, 2023 and March 11, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-form ...

Core Viewpoint - A securities class action lawsuit has been filed against Zynex, Inc. for allegedly misleading investors regarding its revenue practices and product shipments [1][3]. Company Overview - Zynex, Inc. is a medical device company based in Englewood, CO, specializing in electrotherapy devices for pain management and rehabilitation [2]. Lawsuit Details - The lawsuit claims that Zynex shipped products, including electrodes, beyond actual demand, allowing the company to inflate its revenue [3]. - It is alleged that Zynex's practice of filing false claims attracted scrutiny from insurers, including Tricare, which could lead to adverse consequences such as removal from insurer networks and federal penalties [3]. Investor Information - Investors who purchased Zynex securities during the class period (March 13, 2023, to March 11, 2025) have until May 19, 2025, to seek appointment as lead plaintiff [2].